Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.
Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Eupraxia Pharmaceuticals Stock Performance
Shares of EPRX traded down $0.07 during trading hours on Thursday, hitting $3.20. The stock had a trading volume of 387 shares, compared to its average volume of 16,265. The firm has a 50-day moving average price of $3.54 and a 200 day moving average price of $3.16. Eupraxia Pharmaceuticals has a fifty-two week low of $2.20 and a fifty-two week high of $4.48. The firm has a market capitalization of $114.07 million and a price-to-earnings ratio of -4.44.
Wall Street Analysts Forecast Growth
Separately, Craig Hallum began coverage on shares of Eupraxia Pharmaceuticals in a research note on Friday, February 21st. They set a "buy" rating and a $12.00 target price on the stock.
Get Our Latest Analysis on EPRX
About Eupraxia Pharmaceuticals
(
Get Free Report)
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Further Reading
Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.
While Eupraxia Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
